Preferred Label : Nivolumab;
NCIt synonyms : NIVO; Anti-PD-1 Human Monoclonal Antibody MDX-1106; Nivolumab Biosimilar CMAB819; Nivolumab Biosimilar ABP 206; Nivolumab Biosimilar BCD-263;
NCIt definition : A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative
immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with
immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab
binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane
protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed
on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily
expressed on antigen-presenting cells (APCs). This results in the activation of T-cells
and cell-mediated immune responses against tumor cells. Activated PD-1 negatively
regulates T-cell activation and plays a key role in tumor evasion from host immunity.;
UNII : 31YO63LBSN;
CAS number : 946414-94-4;
Drug name : Opdivo;
Molecule name : ONO-4538; MDX-1106; BMS-936558; CMAB819; ABP 206; BCD-263; ONO 4538; BMS 936558; MDX 1106;
Codes from synonyms : 357;
Origin ID : C68814;
UMLS CUI : C3657270;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
- nivolumab [International Nonproprietary Name]
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
- nivolumab [International Nonproprietary Name]
Validated automatic mappings to BTNT
chemical_or_drug_has_mechanism_of_action
concept_is_in_subset
has_target
is_component_of_chemotherapy_regimen
https://www.has-sante.fr/jcms/p_3527277/fr/opdivo-nivolumab-cancer-bronchique-cbnpc
2024
false
false
false
France
evaluation of the transparency committee
Nivolumab
cancer
Malignant Neoplasm
bronchus, nos
neoplasm, malignant
Bronchial
carcinoma, non-small-cell lung
Opdivo
nivolumab
Nivolumab
---
https://www.has-sante.fr/jcms/p_3478087/fr/opdivo-yervoy-ipilimumab/nivolumab-cancer-de-l-oesophage
2023
France
evaluation of the transparency committee
Nivolumab
esophageal neoplasms
Ipilimumab
yervoy
esophagospasm
cancer of esophagus
Childhood Esophageal Carcinoma
neoplasm, malignant
Opdivo
---